Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Exelixis Inc chart...

About the Company

exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.

Exchange

NASDAQ

Website

exelixis.com

$226M

Total Revenue

484

Employees

$7B

Market Capitalization

53.17

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $EXEL News

Exelixis (EXEL) Q4 Earnings Beat on Lower R&D Spend, Sales Miss

1mon ago, source: Hosted on MSN

Exelixis, Inc. EXEL reported earnings of 33 cents per share in the fourth quarter of 2023, which beat the Zacks Consensus Estimate of 31 cents. The company posted a net loss of 3 cents per share ...

Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?

2mon ago, source: Hosted on MSN

Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an update on its business. The company announced preliminary FY23 revenue of $1.83 billion versus ...

Exelixis, Inc.: Exelixis Earnings: Cabometyx Posts Strong Sales, but Patent Expirations Present Long-Term Concerns

1mon ago, source: Yahoo Finance

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic ...

Exelixis (NASDAQ: EXEL)

3d ago, source: The Motley Fool

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx ...

Exelixis, Inc. (EXEL) Q4 2023 Earnings Call Transcript

1mon ago, source: Seeking Alpha

Good day, ladies and gentlemen, and welcome to the Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results Conference Call. My name is Tawanda, and I will be your operator for today.

Exelixis: Q4 Earnings Snapshot

1mon ago, source: Times Union

ALAMEDA, Calif. (AP) — ALAMEDA, Calif. (AP) — Exelixis Inc. (EXEL) on Tuesday reported fourth-quarter earnings of $85.5 million. On a per-share basis, the Alameda, California-based company ...

Exelixis, Inc. (EXEL)

1mon ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Exelixis' Growth Trajectory Depends on Leading Innovations in Cancer Treatments

20d ago, source:

In recent years, the company's management has continued to delight investors with significant growth in its commercial ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...